Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
PORTSMOUTH, N.H.--(BUSINESS WIRE)-- Albany International Corp. (NYSE: AIN) announced today that it is exploring strategic alternatives for its structures assembly business, including a potential sale ...
Albany International Initiates Review of Strategic Alternatives for Structures Assembly Business; Announces Loss Reserve Adjustment for CH-53K Program; Schedules Earnings Release Date Third-Quarter ...
Editor’s Note: The Trump administration has clarified that it will use Section 32 tariff revenue, which typically supports child nutrition programs, to extend funding for WIC during the shutdown — ...
OKLAHOMA CITY (KFOR) – Artificial intelligence is reportedly making its way into a traditional Medicare pilot program that six states, including Oklahoma, will test out. It has to do with patients ...
FEED will allow Soldiers to use their meal entitlements outside of traditional Army-operated dining facilities for the first time. During the pilot, 200 Soldiers from the 61st Quartermaster Battalion ...
Starting in January, Medicare will test out an artificial intelligence (AI) pilot program to decide whether patients get certain procedures covered or not. The Centers for Medicare & Medicaid Services ...
Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback